Currently, there are 227.28M common shares owned by the public and among those 226.37M shares have been available to trade.
The company’s stock has a 5-day price change of 12.62% and 26.00% over the past three months. CWK shares are trading 40.46% year to date (YTD), with the 12-month market performance up to 83.66% higher. It has a 12-month low price of $7.28 and touched a high of $13.99 over the same period. CWK has an average intraday trading volume of 1.92 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 15.13%, 15.54%, and 33.28% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Cushman & Wakefield plc (NYSE: CWK) shares accounts for 96.07% of the company’s 227.28M shares outstanding.
It has a market capitalization of $3.48B and a beta (3y monthly) value of 1.31. The stock’s trailing 12-month PE ratio is 39.78, while the earnings-per-share (ttm) stands at $0.38. The company has a PEG of 3.98 and the debt-to-equity ratio at 1.98. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.04% over the week and 3.39% over the month.
Earnings per share for the fiscal year are expected to increase by 3.65%, and 34.53% over the next financial year. EPS should shrink at an annualized rate of 10.00% over the next five years, compared to 32.16% over the past 5-year period.
Looking at the support for the CWK, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on April 10, 2024, with the firm’s price target at $13. Raymond James was of a view on April 03, 2024 that the stock is Outperform, while Wolfe Research gave the stock Outperform rating on December 08, 2023, issuing a price target of $12. UBS on their part issued Neutral rating on April 17, 2023.
